Selumetinib, a MEK inhibitor, in combination with Dacarbazine does not effective in uveal melanoma
The phase 3 SUMIT study of Selumetinib in combination with Dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint of progression free survival.
Th ...
read article